UroGen Pharma Ltd. (URGN): EPS (Basic)

Annual figures by period end, from SEC filings.

-$3.19
Year ended 2025-12-31
2021-12-31: -$4.962022-12-31: -$4.812023-12-31: -$3.552024-12-31: -$2.962025-12-31: -$3.19-$3.19
2021-12-31 EPS (Basic) (USD per share) 2025-12-31
Period endedEPS (Basic)Change YoYSource filing
2025-12-31-$3.19n/m2026-03-02, From 2025-01-01
2024-12-31-$2.96n/m2026-03-02, From 2024-01-01
2023-12-31-$3.55n/m2025-03-10, From 2023-01-01
2022-12-31-$4.81n/m2024-03-14, From 2022-01-01
2021-12-31-$4.96n/a2023-03-24, From 2021-01-01

EPS (Basic) at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedEPS (Basic)Change YoY
UroGen Pharma Ltd. (URGN)2025-12-31-$3.19n/m
Zevra Therapeutics, Inc. (ZVRA)2025-12-31$1.40n/m
Zymeworks Inc. (ZYME)2025-12-31-$1.08n/m
Gyre Therapeutics, Inc. (GYRE)2025-12-31$0.06-57.1%
Xencor Inc (XNCR)2025-12-31-$1.24n/m
Siga Technologies Inc (SIGA)2025-12-31$0.33-60.2%
Lifecore Biomedical, Inc. (LFCR)2025-05-25-$1.27n/m
Cytokinetics Inc (CYTK)2025-12-31-$6.54n/m
Standard Biotools Inc. (LAB)2025-12-31-$0.20n/m

Compare URGN, ZVRA, ZYME, GYRE side by side · Screen every company in Pharmaceutical Preparations ↗